SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin trades jubilantly on the bourses

20 Aug 2015 Evaluate

Lupin is currently trading at Rs. 1900.00, up by 104.65 points or 5.83% from its previous closing of Rs. 1795.35 on the BSE.

The scrip opened at Rs. 1820.00 and has touched a high and low of Rs. 1939.90 and Rs. 1815.50 respectively. So far 263697 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2112.00 on 08-Apr-2015 and a 52 week low of Rs. 1214.35 on 20-Aug-2014.

Last one week high and low of the scrip stood at Rs. 1939.90 and Rs. 1750.00 respectively. The current market cap of the company is Rs. 85493.45 crore.

The promoters holding in the company stood at 46.59% while Institutions and Non-Institutions held 43.57% and 9.84% respectively.

Drug major Lupin has opened a research and development (R&D) centre for inhalation products at Coral Springs in Florida, the US.  The facility will focus on the R&D of inhalation products for the treatment of asthma, allergic rhinitis, chronic obstructive pulmonary diseases and other lung diseases.

With the talent and resources Florida provides, the company’s Coral Springs expansion will further strengthen its ability to bring quality, affordable pharmaceuticals to patients in the United States and other key markets globally.

Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded & generic formulations, APIs and biotechnology products.

Lupin Share Price

2395.00 52.85 (2.26%)
29-Jun-2026 14:58 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1871.90
Dr. Reddys Labs. 1378.40
Cipla 1460.00
Zydus Lifesciences 1115.90
Lupin 2395.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: